Search results
Results from the WOW.Com Content Network
On Tuesday, Danaher Corp (NYSE:DHR) reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the consensus of $5.59 billion. Non-GAAP core revenue increased by 0.5%, compared ...
On Tuesday, Danaher Corp (NYSE:DHR) reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the consensus of $5.59 billion. Guidance: Danaher reaffirms that in fiscal year ...
Danaher (DHR) Q4 results to reflect gains from better-than-expected segmental top-line performances, mainly Diagnostics and Life Sciences. Cost inflation is likely to have been affecting margins.
Danaher (DHR) delivered earnings and revenue surprises of 14.29% and 8.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Danaher's (DHR) Q3 results are expected to reflect a healthy demand for products in Life Sciences and Diagnostics segments. Also, Cytiva is anticipated to have aided core sales.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us